September 4, 2019 — Global Diagnostics Australia (GDA), a subsidiary of the Integral Diagnostics Group (IDX), has adopted artificial intelligence (AI) applications into its radiology workflow, and is one of the first diagnostic imaging companies in Australia to do so. GDA has partnered with AI company Aidoc to incorporate their algorithms into GDA's care management pathway. These AI applications will expedite patient diagnosis and treatment for several head, neck and chest conditions.
Aidoc's "Always-on" AI solution analyzes medical images and prioritizes the patient list to ensure that the most critical are diagnosed and treated first. The introduction of AI by GDA marks a milestone for Aidoc as it expands into Australia.
Aidoc has recently received Therapeutic Goods of Australia (TGA) clearance, and already has U.S. Food and Drug Administration (FDA) approvals and European Union CE markings on AI applications for three medical conditions: intracranial hemorrhage, pulmonary embolism and cervical-spine fracture.
As well as onsite hospital radiology services, GDA also provides teleradiology services to remote and rural parts of Western Australia. Using AI to flag critical findings for these patients helps expediate their care when time is critical, or when they need to be transferred to larger facilities in the metropolitan area for urgent treatment.
"The increase in demand for radiology services in regional areas has created an increased workload for radiologists servicing the regions. AI is being used to effectively triage the truly urgent cases, and this allows the radiologist to appropriately prioritize patients in most need of care. The application provides additional peace of mind for radiologists, patients and for referring doctors, that urgent life-threatening conditions are found and treated faster. AI has arrived and it is here to stay, it is going to materially improve patient care and service well into the future," stated Nazar Bokani, M.D., clinical director, GDA.
For more information: www.aidoc.com
April 17, 2024 
